// App-Quantinova.ai

TPS2611 : A randomized Phase 2a study to assess pharmacodynamics, antitumor activity and safety of intravenous BAL101553, a novel microtubule inhibitor, at two dose levels in adult patients with selected advanced solid tumors.

Researchers

Presenter

  • Rebecca Sophie Kristeleit

Principal Investigators

  • Noor R Md Haris

  • Stephanie Anderson

  • Felix Bachmann

  • Martina Maurer

  • Anne Schmitt-Hoffmann

  • Heidi A Lane

  • Marc Frederick Engelhardt

  • T.R. Jeffry Evans

  • Ruth Plummer

  • Maria Jose de Miguel Luken

  • Manolo D'Arcangelo

  • Julie MacDonald

  • Nicholas F. Brown

  • Alan Hilary Calvert

  • Alison L. Hannah

  • L Rhoda Molife

  • Ishtiaq Husain Zubairi

  • Judy W. King

Medical Centers

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

  • University College London, London, United KingdomThe Royal Marsden/Institute of Cancer Research, Sutton, Surrey, United KingdomBasilea Pharmaceutica International Ltd, Basel, Switzerland

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Oncology Clinical Trial Consulting, Sebastopol, CA

Locations

  • United States

  • Spain

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Breast cancer

  • Non Small Cell Lung cancer

Biomarkers

  • Circulating tumor cells

Drug/Treatment

  • BAL-101553

Outcome

  • N/A

Study Design

  • randomized

  • pharmacodynamics

Phase

  • II

Study Id's

  • NCT01397929

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved